WebTumor suppressor SMARCA4 (BRG1), a key SWI/SNF chromatin remodeling gene, is frequently inactivated in cancers and is not directly druggable. We recently uncovered that SMARCA4 loss in an ovarian cancer subtype causes cyclin D1 deficiency leading to susceptibility to CDK4/6 inhibition. WebFeb 1, 2024 · SMARCA4, as one of the most important mutually exclusive catalytic ATPase subunits, provides energy for the chromatin remodeling process by using its ATPase enzymatic function to activate or repress transcription [16, 35] (Fig. 3).Its alterations have been identified in various common tumors, such as lung cancer, colon adenocarcinoma, …
Hereditary Cancer Syndromes Genetics and Hereditary Cancers
WebApr 28, 2024 · Ovarian carcinoma is an extremely rare malignancy in children, often developing on the underlying inherited background. Female carriers of pathogenic germline mutations of SMARCA4 are at risk of an aggressive type of undifferentiated ovarian cancer called small cell carcinoma of the ovary, hypercalcemic type (SCCOHT). Regardless of … WebExpression of SMARCA4 (BAF190, BRG1, FLJ39786, hSNF2b, SNF2, SNF2-BETA, SNF2L4, SNF2LB, SWI2) in cancer tissue. The cancer tissue page shows antibody staining of the protein in 20 different cancers. ... BREAST CANCER CARCINOID CERVICAL CANCER COLORECTAL CANCER ENDOMETRIAL CANCER GLIOMA HEAD AND NECK CANCER … ina garten tomato soup creamy
Abstract 3844: Anti-tumor efficacy of SMARCA degraders in pre …
WebDec 3, 2024 · SMARCA4 alterations typify the ultra-rare small cell carcinomas of the ovary hypercalcemic type (SCCOHT) and SMARCA4-deficient thoracic and uterine sarcomas; … WebFeb 4, 2024 · SMARCA4, encoding a SWI/SNF catalytic ATPase subunit, is inactivated by mutations or other mechanisms in different cancers, including non-small cell lung cancer (NSCLC), breast cancer, glioblastoma, and others 4 – 7. However, the underlying mechanisms of SMARCA4 loss in driving tumorigenesis are currently unclear. WebApr 10, 2024 · Deficiency of SMARCA4, a member of the SWI/SNF chromatin remodeling complex, has been described in a subset of undifferentiated gastroesophageal carcinomas with aggressive clinical course. The full spectrum and frequency of SMARCA4 mutations in gastroesophageal cancer are unknown. We interrogated our institutional database and … incentive\u0027s nb